Yumanity Therapeutics Inc

+0.46 (+5.31%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)94.10M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.93 Million
Adjusted EPS-$1.13
See more estimates
10-Day MA$9.16
50-Day MA$9.99
200-Day MA$14.41
See more pivots

Yumanity Therapeutics Inc Stock, NASDAQ:YMTX

40 Guest Street, Suite 4410, Boston, Massachusetts 02135
Phone: +1.617.409.5300
Number of Employees: 44


Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. It is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. Its platform is based on technology, which enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which usually results from an aberrant accumulation of misfolded proteins in the brain. The company was founded by Susan Lindquist and Tony Coles in December 2014 and is headquartered in Boston, MA.